GWAS for nicotine cessation mentioned above examined different nicotine cessation methods: denicotinized cigarettes (Drgon, Johnson, et al., 2009), mecamylamine/nicotine replacement (G. R. Uhl, et al., 2007) and bupropion (G. R. Uhl, Liu, et al., 2008). Using data from these studies a “quit success” genotype score was developed to assess the cumulative genetic contribution to quit success (Rose, Behm, Drgon, Johnson, & Uhl, 2010). This study found that there was an interaction between this quit success score, nicotine dose during pre-cessation treatment, and the degree of nicotine dependence. Those individuals with high quit-success genotype scores had relatively high abstinence rates (20-25 % at 10 weeks) independent of nicotine replacement dose. Those individuals with low quit-success genotype scores had highly differential responses to nicotine doses depending on level of dependence – low dependence individuals had far greater abstinence rates at the lower nicotine dose (33% at the low dose vs. 10% at the high dose), while high dependence individuals had greater abstinence rates at the higher nicotine dose (9% at the low dose vs. 22% at the high dose). This study suggests
